Ploidy status rarely changes in myeloma patients at disease progression

Leukemia Research

Volumn 30, Issue 3, 2006, Pages 266-271

  Chng, W J ^a,g   Winkler, J M ^b   Greipp, P R ^b   Jalal, S M ^b   Bergsagel, P L ^a   Chesi, M ^a   Trendle, M C ^c   Ahmann, G J ^a   Henderson, K ^b   Blood, E ^d   Oken, M M ^e   Hulbert, A ^f   Wier, S A Van ^a   Santana Davila R ^b   Kyle, R A ^b   Gertz, M A ^b   Lacy, M Q ^b   Dispenzieri, A ^b   Fonseca, R ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c Missouri Cancer Associates   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e North Memorial Cancer Center   (United States)

^f VA MEDICAL CENTER   (United States)

^g NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Disease progression; DNA index; Flow cytometry; Myeloma; Ploidy

Indexed keywords

DNA;

ARTICLE; ARTIFACT; CANCER GROWTH; CHROMOSOMAL INSTABILITY; CLINICAL ARTICLE; DIPLOIDY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MYELOMA; PLOIDY; PRIORITY JOURNAL;

DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MULTIPLE MYELOMA; PLOIDIES;

EID: 30144438760     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.07.004     Document Type: Article

References (30)

1. W.M. Kuehl, and P.L. Bergsagel Multiple myeloma: evolving genetic events and host interactions Nat Rev Cancer 2 2002 175 187
2. M. Hallek, P.L. Bergsagel, and K.C. Anderson Multiple myeloma: increasing evidence for a multistep transformation process Blood 91 1998 3 21
3. R. Fonseca, R.J. Bailey, G.J. Ahmann, S.V. Rajkumar, J.D. Hoyer, and L.A. Lust Genomic abnormalities in monoclonal gammopathy of undertermined significance Blood 100 2002 1417 1424
4. H. Avet-Loiseau, T. Facon, A. Daviet, C. Godon, M.J. Rapp, and J.L. Harrouseau 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undertermined significance delineate a multistep process for the oncogenesis of multiple myeloma Cancer Res 59 1999 4546 4550
5. R. Konigsberg, J. Ackermann, H. Kaufmann, N. Zojer, E. Urbauer, and E. Kromer Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance Leukaemia 14 2000 1975 1979
6. H. Avet-Loiseau, J.Y. Li, N. Morineau, T. facon, C. Brigaudeau, and J.L. Harousseau Monosomy 13 is associated with the transition of monoclonal gammopathy of undertermined significance to multiple myeloma Blood 94 1999 2583 2589
7. P. Bernasconi, P.M. Cavigliano, M. Boni, C. Astori, S. Calatroni, and I. Giardini Long term follow-up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance Br J Haematol 118 2002 545 549
8. R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P.L. Bergsagel, and M. Chesi Genetics and cytogenetics of multiple myeloma: a workshop report Cancer Res 64 2004 1546 1558
9. J. Drach, J. Ackermann, E. Fritz, E. Kromer, R. Schuster, and H. Gisslinger Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy Blood 92 1998 802 809
10. A. Neri, L. Baldini, D. Trecca, L. Cro, E. Polli, and A.T. Maiolo P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy Blood 81 1993 128 135
11. J. Ackermann, P. Meidlinger, N. Zojer, H. Gisslinger, H. Ludwig, and H. Huber Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance Br J Haematol 103 1998 1161 1163
12. P. Liu, T. Leong, L. Quam, D. Billadeau, N.E. Kay, and P.R. Greipp Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial Blood 88 1996 2699 2706
13. S. Bezieau, H. Avet-loiseau, J.P. Moisan, and R. Bataille Activating Ras mutations in patients with plasma-cell disorders: a reappraisal Blood 2003 1101 1102
14. P. Corradini, M. Ladetto, C. Voena, A. Palumbo, G. Inghirami, and D.M. Knowles A mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias Blood 1993 2708 2713
15. H. Kaufmann, J. Ackermann, C. Baldia, T. Nosslinger, R. Wieser, and S. Seidl Both IgH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma Leukaemia 18 2004 1879 1882
16. R. Fonseca, C.S. Debes-Marun, E.B. Picken, G.W. Dewald, S.C. Bryant, and J.M. Winkler The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma Blood 102 2003 2562 2567
17. C.S. Debes-Marun, G.W. Dewald, S. Bryant, E. Picken, R. Santana-Davila, and N. Gonzalez-Paz Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma Leukaemia 2003 427 436
18. N.V. Smadja, C. Fruchart, F. Isnard, F. Louvet, J.L. Dutel, and N. Cheron Chromosomal analysis in multiple myeloma: cytogenetic evidence of 2 different diseases Leukaemia 12 1998 960 969
19. B. Saez, J.I. Martin-Subero, F. Guillen-Grima, M.D. Odero, F. Prosper, and J.C. Cigudosa Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes Leukaemia 18 2004 654 657
20. M.M. Oken, T. Leong, R.E. Lenhard Jr., P.R. Greipp, N.E. Kay, and B. Van Ness The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486 Cancer 86 1999 957 968
21. P.R. Greipp, M.C. Trendle, T. Leong, M.M. Oken, B. Van Ness, and R.A. Kyle Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk lymphoma 35 1999 83 89
22. G.J. Ahmann, S.M. Jalal, A.L. Juneau, E.R. Christenson, C.A. Hanson, and G.W. Dewald A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies Cancer Genet Cytogenet 101 1998 7 11
23. R. Fonseca, C.S. Debes-Marun, E.B. Picken, G.W. Dewald, S.C. Bryant, and J.M. Winkler The recurrent IgH translocations are highly associated with non-hyperdiploid variant multiple myeloma Blood 102 2003 2562
24. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL, et al. A validated FISH trisomy index demonstrates the hyperdiploid and non-hyperdiploid dichotomy in MGUS. Blood prepublished online May 26, 2005; DOI 101182/blood-2005-02-0761.
25. J.F. San Miguel, R. Garcia-Sanz, M. Gonzalez, and A. Orfao DNA cell content studies in multiple myeloma Leuk Lymphoma 23 1996 33 41
26. J. Almeida, A. Orfao, G. Mateo, M. Ocqueteau, R. Garcia-Sanz, and M.J. Moro Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance Path Biol 47 1999 119 127
27. T. Kuukasjarvi, M. Tanner, S. Pennanen, R. Karhu, O.P. Kallioniemi, and J. Isola Genetic changes in intraductal breast cancer detected by comparative genomic hybridization Am J Pathol 150 1997 1465 1471
28. F.M. Waldman, S. De vries, K.L. Chew, D.H Moore II, K. Kerlikowske, and B.M. Ljung Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences J Natl Cancer Inst 92 2000 313 320
29. T. Kuukasjarvi, R. Karhu, M. Tanner, M. Kahkonen, A. Schaffer, and N. Nupponen Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer Cancer Res 57 1997 1597 1604
30. D.G. Albertson, C. Collins, F. McCormick, and J.W. Gray Chromosome aberrations in solid tumors Nat Genet 34 2003 369 376